key: cord-0054495-domvoa2g
authors: Prisco, Sasha Z.; Thenappan, Thenappan; Prins, Kurt W.
title: Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
date: 2020-12-28
journal: JACC Basic Transl Sci
DOI: 10.1016/j.jacbts.2020.07.011
sha: 0de455689f9fe841060cb31378c7e2150fd3be5b
doc_id: 54495
cord_uid: domvoa2g

Right ventricle (RV) dysfunction is the strongest predictor of mortality in pulmonary arterial hypertension (PAH), but, at present, there are no therapies directly targeting the failing RV. Although there are shared molecular mechanisms in both RV and left ventricle (LV) dysfunction, there are important differences between the 2 ventricles that may allow for the development of RV-enhancing or RV-directed therapies. In this review, we discuss the current understandings of the dysregulated pathways that promote RV dysfunction, highlight RV-enriched or RV-specific pathways that may be of particular therapeutic value, and summarize recent and ongoing clinical trials that are investigating RV function in PAH. It is hoped that development of RV-targeted therapies will improve quality of life and enhance survival for this deadly disease.

, and the response of the RV to PAHspecific therapy determines survival (4, 5) . Moreover, RV dysfunction is not solely caused by increased afterload, as some PAH patients exhibit progression of RV dysfunction despite treatment with pulmonary vasodilators (6, 7) . Furthermore, patients with systemic sclerosis-associated PAH (SSc-PAH) have worse RV function-and consequently increased mortality-compared with patients who have idiopathic PAH (IPAH), despite having similar severity of pulmonary vascular disease (6, 8) . Unfortunately, no currently available PAH therapy directly targets the RV. Therefore, there is an unmet need to combat the mechanisms underlying RV dysfunction directly to improve long-term outcomes in PAH.

In addition to PAH, RV dysfunction is prognostic in the 2 leading causes of pulmonary hypertension (PH):

PH caused by left heart disease (World Health Organization [WHO] Group 2) and lung disease (WHO Group 3) (9) (10) (11) . RV function predicts mortality (12, 13) and is affected independent of afterload in Group 2 PH (14) . Despite having less severe pulmonary vascular disease than patients with PAH, Group 3 PH patients have disproportionate RV dysfunction and poor survival (15) . The presence of RV dysfunction in Group 3 PH also identifies patients at high risk of poor outcomes (11, 16) . Unfortunately, PAH-specific therapies do not significantly improve exercise capacity or reduce symptom burden in Group 2 and 3 PH (17) .

Thus, RV-directed therapy may be beneficial for these prevalent and currently untreatable causes of PH.

Mechanistic dissections of RV dysfunction have lagged behind our understanding of left ventricular (LV) dysfunction. This is exemplified by the fact that there are multiple therapies with proven survival benefits for LV failure (18, 19) but no approved drugs for RV dysfunction. Importantly, the use of standard therapies for LV failure, such as beta blockers and targets of the renin-angiotensin-aldosterone system (RAAS), are not indicated or potentially contraindicated in patients with PAH and RV dysfunction (20, 21) . Thus, understanding the differences between the RV and LV may be important to define RV-directed therapies ( Figure 1 , Table 1 ).

There are developmental, anatomic, and functional differences between the RV and LV ( Figure 1 ) that may provide insight into ways to enhance ventriclespecific function ( Figure 2 , Table 1 ). Developmentally, the LV originates first from the splanchnic mesoderm within the primary heart field (22) , whereas the RV develops second from the extracardiac mesoderm within the secondary heart field (23) . The prenatal RV is thick walled and generates high pressures to support fetal blood flow (24) . After birth, the pulmonary circulation becomes a low pressure circuit (25),

whereas the systemic circulation becomes a high pressure system, which leads to relative LV hypertrophy (26) . Ultimately, the RV becomes a thin-walled, crescent-shaped chamber, whereas the LV takes a muscular bullet shape (27) . Furthermore, there are dissimilarities in cardiomyocyte arrangement that lead to differences in contractility between the 2 ventricles. The adult RV has 2 layers of cardiomyocytes: a circumferential layer that brings the RV free wall toward the interventricular septum and a deeper layer of vertical fibers that result in longitudinal shortening, which accounts for 75% of the total RV contractility (28). In contrast, the LV has 3 myocardial layers. LV contraction is a function of radial fiber thickening, longitudinal fiber shortening, and oblique fiber thickening (29) . Circumferential and longitudinal shortening contribute to 67% and 33% of total LV contractility, respectively (30) . Moreover, there are differences in ventricular perfusion, as the RV is perfused throughout the cardiac cycle, whereas the LV is only perfused during diastole (31) . Although the normal RV and LV have similar coronary flow reserves of 400% to 500% (32) (33) (34) (35) , the RV has lower baseline oxygen consumption and greater oxygen extraction reserve, which lowers its risk of ischemic injury caused by decreased coronary flow (31) . However, the pressure-overloaded RV is more susceptible to ischemia, with acute or chronic increases in afterload as elevated RV afterload reduces the systolic RV perfusion gradient. This curtails overall RV perfusion because the RV is normally perfused during both systole and diastole (31) . Finally, there are important anatomic differences between the ventricles that alter their response to preload and afterload. The RV is thinner and has lower volume to wall surface area, which makes the RV more compliant and better adapted to initial volume increases but renders it unable to accommodate afterload increases as well as the LV (36). This is supported by a study of isolated rat hearts that shows the LV has a higher afterload reserve than the RV (37) .

There are divergent molecular responses between RV and LV failure documented in animal and human studies (27, 38, 39) . In brief, there are differences in adrenergic signaling regulation as b1and a1-adenergic and dopamine-1 receptors are downregulated in the pressure overloaded RV, which leads to a diminished inotropic response (38, 39) . Although there is also downregulation of b1-adenergic receptors in LV dysfunction (40) , a1-adrenergic receptors are actually upregulated and increase contractility in the pressure overloaded LV (27, 38, 39, 41) . Conversely, a1-receptor signaling decreases inotropy in the overloaded RV (27, 38, 39) .

Furthermore, there are dissimilarities in the response to catecholamines, as only the LV develops hypertrophy following norepinephrine infusion (27, 38) . 

EXPERIMENTAL MODELS OF PAH. Several commonly used preclinical models of PAH are discussed in the following sections. (79) . We also showed t-tubule disarray and downregulation of junctophilin-2 in the monocrotaline RV (80) . Colchicine treatment to combat pathological microtubule remodeling increases junctophilin-2, partially corrects t-tubule architecture, and improves RV function in monocrotaline rats, albeit in the setting of less severe pulmonary vascular remodeling (80) . These data suggest that t-tubule remodeling promotes RV dysfunction, but both 

At baseline, RV has higher collagen content (75) and different expression of matrix metalloproteinases and extracellular matrix proteins (76) compared with the LV. Antifibrotic therapies that are effective in the LV (pirfenidone and eplerenone) do not reverse fibrosis in the RV (57, 72) .

Inflammation RV has more macrophages and dendritic cells at baseline compared with the LV (95) .

Estrogen signaling In the dysfunctional RV, the beneficial effects of estrogen are predominately mediated by ER-a (98), but in LV pressure overload, stimulation of ER-b normalizes LV ejection fraction (106) .

Ischemia RV is perfused during both systole and diastole, whereas the LV is only perfused during diastole (31) . At baseline, RV has a reduced microvascular bed with less tissue perfusion compared with the LV (135). There may be decreased angiogenesis during RV failure (110, (121) (122) (123) .

There are baseline differences in miRNA expression between the RV and LV (140) . RV-specific miRNAs that are dysregulated during RV dysfunction: miR-21, -28, -34a, -93, -126/VEGF, -127, -130a, -146b, -148a, -197, -208/ Mef2c, -221, and let-7e (39, 133, (140) (141) (142) (143) 145) .

studies have the caveat of reduced PAH severity (79, 80) . Nonetheless, strategies to normalize junctophilin-2 levels and restore t-tubule architecture may enhance RV function.

SARCOMERIC ABNORMALITIES. There is emerging evidence that altered sarcomere function promotes RV dysfunction in PAH. In pulmonary artery-banded rats, RV myocardial stiffness is observed in both mild and severe dysfunction (62 expression, leading to more severe heart failure following pressure overload in mice (86) . Importantly, this phenotype is reversed by either upregulation of regnase-1 expression or administration of an anti-IL-6 receptor antibody (86) . Clearly, there is evidence that inflammation negatively affects cardiac function. 

Prisco et al. Clinical trials investigating the effects of antagonizing IL-1 (anakinra), IL-6 (tocilizumab), and CD20 on B cells (rituximab) in PAH are completed ( Table 3) . Larger trials may be needed to determine the utility of FAO inhibitors in RV dysfunction in PAH. Prisco et al. Recruiting *Some of the trials that are active but not currently recruiting as of May 2020 may be due to the current COVID-19 pandemic. †Trial in patients with severe functional regurgitation.

CMR ¼ cardiovascular magnetic resonance imaging; CPET ¼ cardiopulmonary exercise testing; DHEA ¼ dehydroepiandrosterone; Ees ¼ end-systolic elastance; FDG-PET ¼ fluorodeoxyglucose-positron emission tomography; NT-proBNP ¼ N-terminal-pro-brain natriuretic peptide; PVR ¼ pulmonary vascular resistance; RHC ¼ right heart catheterization; RV ¼ right ventricle; RVEF ¼ right ventricular ejection fraction; TAPSE ¼ tricuspid annular plane systolic excursion; WHO ¼ World Health Organization.

Prisco et al. heightens RV contractility in isolated rodent hearts (165) . The beneficial effects of PDE5 inhibitors on the RV and exercise capacity are also supported by a randomized controlled trial that investigated the effects of sildenafil (a PDE5 inhibitor) therapy on exercise performance in patients with PH due to LV systolic function (166) . In this trial, sildenafil treatment heightened maximal volume of oxygen consumption, exercise cardiac output, and RV ejection fraction at rest and at peak exercise (166) . However, the significant reduction in pulmonary vascular resistance needs to be considered when interpreting the change in RV function with sildenafil therapy in these patients.

Certainly, further research is needed to understand the mechanisms by which exercise improves RV function in PAH and other PH subgroups. Several ongoing clinical trials are investigating the role of exercise on RV function ( Table 3) ; it is hoped that they will provide more insight moving forward.

Multiple clinical trials have investigated or are currently investigating the targets of RV dysfunction discussed in this review (Table 3) . However, majority of these clinical trials are not specifically investigating RV function as a primary outcome.

There are some encouraging preliminary findings, as carvedilol enhances RV function (167) and decreases RV glucose uptake (168) . In addition, ranolazine (118) and trimetazidine show trends for improvement in RV function. It is hoped that 1 or more of these trials will identify targets for RV failure to improve outcomes in patients with PAH and, eventually, patients with PH due to other causes.

RV dysfunction is the strongest predictor of mortality in PAH (1-3), but none of the currently available PAH therapies directly target the failing RV. Here, we discussed the known molecular mechanisms involved in RV dysfunction in PAH to delineate potential targets for RV-enhancing or RV-directed therapies (Central Illustration). Furthermore, we highlighted the important differences between the RV and LV, which may be particularly relevant for developing RVdirected therapies. Finally, we summarized recent and ongoing clinical trials targeting the molecular mechanisms of RV dysfunction in PAH. We hope that ongoing and future studies will identify RV-targeted therapies that will enhance quality of life and improve survival in PAH.

ACKNOWLEDGMENT The authors thank Cynthia Faraday for her assistance with designing the figures. 

Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy

Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension

Right ventricular dysfunction in systemic sclerosisassociated pulmonary arterial hypertension

Differences in right ventricular functional changes during treatment between systemic sclerosis-associated pulmonary arterial hypertension and idiopathic pulmonary arterial hypertension

Right ventricular functional reserve in pulmonary arterial hypertension

Increasing incidence and prevalence of World Health Organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario

Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort

Aetiology and outcomes of severe right ventricular dysfunction

Right ventricular function in heart failure with preserved ejection fraction: a communitybased study

Right heart dysfunction in heart failure with preserved ejection fraction

Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction

Disproportionate right ventricular dysfunction and poor survival in group 3 pulmonary hypertension

Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease

Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and metaanalysis

ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study

Captopril in primary pulmonary hypertension

Signal transduction in early heart development (II): ventricular chamber specification, trabeculation, and heart valve formation

The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field

Quantitative assessment of right and left ventricular growth in the human fetal heart: a pathoanatomic study

Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat. I. Hypertrophy, hyperplasia, and binucleation of myocytes

Longitudinal shortening accounts for the majority of right ventricular contraction and improves after pulmonary vasodilator therapy in normal subjects and patients with pulmonary arterial hypertension

How does the left ventricle work? Ventricular rotation as a new index of cardiac performance

The relative impact of circumferential and longitudinal shortening on left ventricular ejection fraction and stroke volume

Right Ventricular perfusion: physiology and clinical implications

Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans

Right and left ventricular oxygen metabolism in open-chest dogs

Right and left ventricular O2 uptake during hemodilution and beta-adrenergic stimulation

Alpha-adrenergic vasoconstrictor tone limits right coronary blood flow in exercising dogs

Biomechanics of the right ventricle in health and disease

Comparison between left and right heart function in the isolated biventricular working rat heart

Right ventricular phenotype, function, and failure: a journey from evolution to clinics

Molecular mechanisms of right ventricular failure

New insights in cardiac b-adrenergic signaling during heart failure and aging

Cardiac alpha 1-adrenergic drive in pathological remodelling

Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives

The angiotensin-converting enzyme 2/angiogenesis

Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension

Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotalineinduced right ventricular hypertrophy in rats

Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway

Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats

Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension

Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension

Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart

Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics

A potential therapeutic role for angiotensinconverting enzyme 2 in human pulmonary arterial hypertension

Right ventricular myocardial stiffness in experimental pulmonary arterial hypertension: relative contribution of fibrosis and myofibril stiffness

Right ventricular diastolic impairment in patients with pulmonary arterial hypertension

Impairment of Excitation-contraction coupling in right ventricular hypertrophied muscle with fibrosis induced by pulmonary artery banding

Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension

Adverse biventricular remodeling in isolated right ventricular hypertension is mediated by increased transforming growth factor-b1 signaling and is abrogated by angiotensin receptor blockade

A selective transforming growth factor-b ligand trap attenuates pulmonary hypertension

5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure

Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of PA de-banding

Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone

Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension

The specific mineralocorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase-A

Quantitation of collagen in human myocardium

Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies

The structure and function of cardiac t-tubules in health and disease

Junctophilins: a novel family of junctional membrane complex proteins

Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2þ) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension

Colchicine depolymerizes microtubules, increases junctophilin-2, and improves right ventricular function in experimental pulmonary arterial hypertension

Right ventricular myofilament functional differences in humans with systemic sclerosisassociated versus idiopathic pulmonary arterial hypertension

Inflammation in pulmonary arterial hypertension

Inflammation, growth factors, and pulmonary vascular remodeling

Deletion of interleukin-6 attenuates pressure overloadinduced left ventricular hypertrophy and dysfunction

Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca

Cytokine mRNA degradation in cardiomyocytes restrains sterile inflammation in pressure-overloaded hearts

Inflammatory mediators drive adverse right ventricular remodeling and dysfunction and serve as potential biomarkers

Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension

Increased levels of plasma CXC-chemokine ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension

Early inflammatory response during the development of right ventricular heart failure in a rat model

Long-term pressureinduced cardiac hypertrophy: capillary and mast cell proliferation

Opposite effects of training in rats with stable and progressive pulmonary hypertension

Activation of apoptotic pathways in experimental acute afterload-induced right ventricular failure

Exercise preconditioning prevents MCT-induced right ventricle remodeling through the regulation of TNF superfamily cytokines

Transcriptomic profiles reveal differences between the right and left ventricle in normoxia and hypoxia

IL-1 Blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB/II pilot study

Sex, gender, and sex hormones in pulmonary hypertension and right ventricular failure

Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones

Estrogen maintains mitochondrial content and function in the right ventricle of rats with pulmonary hypertension

Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension

Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry

Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era

Determinants of right ventricular ejection fraction in pulmonary arterial hypertension

Estrogen rescues heart failure through estrogen receptor beta activation

Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men

The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure

Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension

Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics

Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle

PPARg agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation

Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension

BMPR2 dysfunction impairs insulin signaling and glucose homeostasis in cardiomyocytes

Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension

Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study

Right coronary artery flow impairment in patients with pulmonary hypertension

Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension

Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure

Heart and lung VEGF mRNA expression in rats with monocrotaline-or hypoxia-induced pulmonary hypertension

A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension

Vascular adaptation of the right ventricle in experimental pulmonary hypertension

Right ventricle vasculature in human pulmonary hypertension assessed by stereology

Angiogenesis in skeletal and cardiac muscle

HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease

Molecular mechanisms of hypoxiainducible factor-induced pulmonary arterial smooth muscle cell alterations in pulmonary hypertension

Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart

Hypoxiainducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse

Molecular signature of a right heart failure program in chronic severe pulmonary hypertension

Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats

Downregulation of microRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension

Supracoronary aortic banding improves right ventricular function in experimental pulmonary arterial hypertension in rats by increasing systolic right coronary artery perfusion

Microvascular development in porcine right and left ventricular walls

Mechanisms of oxygen demand/supply balance in the right ventricle

Advances in epigenetics link genetics to the environment and disease

The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials

The emerging role of epigenetics in pulmonary hypertension

Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure

Differential microRNA-21 and microRNA-221 upregulation in the biventricular failing heart reveals distinct stress responses of right versus left ventricular fibroblasts

Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension

A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension

MicroRNA-140 is elevated and mitofusin-1 is downregulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension

Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle

Identification of the long non-coding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension

Histone acetylation and deacetylation

Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats

Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats

Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism

Alterations in cardiac DNA methylation in human dilated cardiomyopathy

Distinct epigenomic features in end-stage failing human hearts

Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension: a pyruvate dehydrogenase kinasedependent shift in mitochondrial metabolism promotes right ventricular fibrosis

Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues

Regulation of murine cardiac 20S proteasomes: role of associating partners

Twodimensional electrophoresis-based characterization of post-translational modifications of mammalian 20S proteasome complexes

Altered proteasome function in right ventricular hypertrophy

Altered ubiquitin-proteasome signaling in right ventricular hypertrophy and failure

Proteomic remodeling of proteasome in right heart failure

Pathophysiology of exercise intolerance in pulmonary arterial hypertension

Efficacy and safety of exercise training in chronic pulmonary hypertension: systematic review and meta-analysis

High-intensity interval training, but not continuous training, reverses right ventricular hypertrophy and dysfunction in a rat model of pulmonary hypertension

Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease

Phosphodiesterase inhibitors for the treatment of pulmonary hypertension

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension

Treatment of group I pulmonary arterial hypertension with carvedilol is safe

Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial

Experimental models of right heart failure: a window for translational research in pulmonary hypertension

Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure

Anastrozole in pulmonary arterial hypertension: a randomized, double-blind, placebocontrolled trial

Phase I safety study of ranolazine in pulmonary arterial hypertension

Rationale and design of the ranolazine PH-RV study: a multicentered randomised and placebo-controlled study of ranolazine to improve RV function in patients with nongroup 2 pulmonary hypertension